AYTU BIOPHARMA, INC Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31)
AYTU BIOPHARMA, INC (AYTU) had Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) of $20.00 million as of 2013-01-11, per its 10-Q filed 2013-01-14.
Discontinued › Notes › Business Combinations
us-gaap:BusinessAcquisitionContingentConsiderationAtFairValue · last filed 2013-01-14
- 2013-01-11: Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) $20.00M.
| Period end | Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) |
|---|---|
| 2013-01-11 | $20.00M 10-Q · filed 2013-01-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |